7 juin 2018

SEEKYO – nouveau membre

SEEKYO® provides solutions to enhance the therapeutic efficacy of anticancer drugs.

Targeting cancer cell and tumor microenvironment specificities, we are developing the next generation of selective drug delivery systems (Antibody Drug Conjugates ADC or Small Molecule Drug Conjugates SMDC) designed to treat solid and hematological cancers.

En savoir plus